Abstract
Background To investigate the impact of the COVID-19 pandemic and infection prevention measures on children visiting emergency departments across Europe.
Methods Routine health data were extracted retrospectively from electronic patient records of children aged <16 years, presenting to 38 emergency departments (ED) in 16 European countries for the period January 2018 – May 2020, using predefined and standardized data domains. Observed and predicted numbers of ED attendances were calculated for the period February 2020 to May 2020. Poisson models and incidence rate ratios (IRR) were used to compare age groups, diagnoses and outcomes.
Findings Reductions in pediatric ED attendances, hospital admissions and high triage urgencies were seen in all participating sites. ED attendances were relatively higher in countries with lower SARS-CoV-2 prevalence (incidence rate ratio (IRR) 2·62, 95% CI 2·19 to 3·13) and in children aged >12 months (12-<24 months IRR 0·89, 95% CI 0·86 to 0·92; 2-<5years IRR 0·84, 95% CI 0·82 to 0·87; 5-<12 years IRR 0·74, 95% CI 0·72 to 0·76; 12-<16 years IRR 0·74, 95% CI 0·71 to 0·77; vs. age <12 months as reference group). The impact on pediatric intensive care admissions (IRR 1·30, 95% CI 1·16 to 1·45) was not as great as the impact on general admissions. Lower triage urgencies were reduced more than higher triage urgencies (urgent triage IRR 1·10, 95% CI 1·08 to 1·12; emergent and very urgent triage IRR 1·53, 95% CI 1·49 to 1·57; vs. non-urgent triage category). Reductions were highest and sustained throughout the study period for children with communicable infectious diseases.
Interpretation: Reductions in ED attendances were seen across Europe during the first COVID-19 lockdown period. More severely ill children continued to attend hospital more frequently compared to those with minor injuries and illnesses, although absolute numbers fell.
Funding: RGN was supported by National Institute of Health Research, award number ACL-2018-021-007.
Trial registry: ISRCTN91495258
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ISRCTN91495258
Funding Statement
RGN was supported by National Institute of Health Research, award number ACL-2018-021-007. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Following initial approval by the UK Health Research Authority, all participating sites obtained approval from their national/local institutional review boards. The need for individual patient informed consent was waived. Data sharing agreements were in place.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
r.nijman{at}imperial.ac.uk, k.honeyford{at}imperial.ac.uk, ruth.b.farrugia{at}gov.mt, katy.rose2{at}nhs.net, bognarzs{at}heimpalkorhaz.hu, danilobuonsenso{at}gmail.com, liviana.dadalt{at}unipd.it, tisham.de08{at}imperial.ac.uk, i.maconochie{at}imperial.ac.uk, niccolo.parri{at}meyer.it, dr98{at}leicester.ac.uk, tobias.alfven{at}ki.se, camille.aupiais{at}aphp.fr, michael.barrett{at}ucd.ie, romain.basmaci{at}aphp.fr, d.borensztajn{at}erasmusmc.nl, c.vasilico{at}salk.at, Sheena.Durnin{at}tuh.ie, patrick.fitzpatrick{at}cuh.ie, fodordr{at}gmail.com, BORJA.GOMEZCORTES{at}osakidetza.eus, susanne.greber-platzer{at}meduniwien.ac.at, romain.guedj{at}aphp.fr, stuart.hartshorn{at}nhs.net, Florian.Hey{at}med.uni-muenchen.de, lin.jankauskaite{at}gmail.com, daniela.kohlfuerst{at}medunigraz.at, mojca.kolnik{at}kclj.si, mdlyttle77{at}gmail.com, patriciamacao{at}chuc.min-saude.pt, maria.i.mascarenhas{at}hff.min-saude.pt, Shrouk{at}doctors.org.uk, uzdresra{at}gmail.com, zanda.pucuka{at}bkus.lv, reis.carlasofia{at}gmail.com, alexis.rybak{at}aphp.fr, malin.ryd-rinder{at}regionstockholm.se, ozlemt{at}hacettepe.edu.tr, canertrn{at}yahoo.com, valtyr{at}landspitali.is, robertovelascozuniga{at}gmail.com, silviabress{at}gmail.com, h.a.moll{at}erasmusmc.nl, r.oostenbrink{at}erasmusmc.nl, luigi.titomanlio{at}aphp.fr
↵^ Membership of the EPISODES study group is provided as supporting information
Data Availability
All study data are available from via URL XXX
